Navigation Links
Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc.
Date:11/27/2007

A business success story has both UCLA and a team of enterprising UCLA scientists envisioning a brighter future for cancer research and patient care.

In 1996, a unique collaboration of leading UCLA scientists led by Dr. Arie Belldegrun founded the biotechnology company Agensys Inc. and the company now stands to reap $537 million through an acquisition by Astellas Pharma Inc., making it one of the largest Los Angeles-based private biotech firms poised to tackle therapeutic, fully human monoclonal antibody oncology research and drug development.

According to Astellas, the acquisition will enable Agensys to become the cornerstone of the companys biologics efforts and will allow the Agensys team to accelerate its discovery and commercial efforts while working to achieve the vision of building a global leader in biologics and oncology.

Agensys, originally known as UroGenesys, was created with $8 million in seed money from private donors and angel investors, many of whom were grateful patients of the UCLA physicians who had helped spur the development of novel gene-based therapies for prostate cancer, the most common cancer in men.

As clinicians and scientists, we wanted to build on the discoveries made in our individual labs to help move cancer research forward from the bench to the bedside, said Belldegrun, founding chairman of Agensys, professor and chief of urologic oncology in the department of urology at the David Geffen School of Medicine at UCLA, and a researcher with UCLAs Jonsson Cancer Center.

The UCLA scientists worked with former president and chief executive officer of Teledyne Technologies Dr. Donald B. Rice, who became CEO of Agensys. They were joined in 1999 by Dr. Aya Jakobovits, who helped develop monoclonal antibody technology at the company. Today, Agensys specializes in the discovery of proprietary targets for a variety of cancer indications and in antibody product development, manufacturing and clinical testing.

Technology developed at UCLA using lines of patented Xenograft mice that can carry and grow human tumors has led to cutting-edge research and drug development for prostate, kidney, bladder and other urologic indications. According to Dr. Owen Witte, director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, who served as founding chairman of the Agensys scientific advisory board, the technology has also been applied for a variety of other types of cancer including pancreatic, lung, colon, breast and ovarian cancers which inspired the companys name change to Agensys in 2001.

We are pleased that our faculty, in addition to regular duties pursuing research, patient care and teaching, were able to bond together and start this biotech company that is now well positioned to become a major player in Los Angeles and the world for drug development, said Dr. Jean DeKernion, chief of the department of urology at the Geffen School of Medicine and a founding director of Agensys.

UCLA was an initial partner in Agensys. Several patents including those for the Xenograft line series (LAPC) and the prostate stem cell antigen (PSCA) tumor target developed by the UCLA scientific founders of Agensys were licensed to the company from UCLA. Today, more than 300 patents have been generated from the LAPC tumor model, some of which have been licensed to pharmaceutical companies around the world.

In addition, the fundamental patent for PSCA, a cell surface marker overexpressed in prostate cancer patients, was also licensed and serves as the basis for the initial products in the Agensys pipeline. In a groundbreaking step for the university, UCLA took equity as partial consideration for this licensing agreement.

The creation of Agensys exemplifies the creativity and drive of UCLAs faculty entrepreneurs, said Kathryn Atchison, UCLA vice provost for intellectual property and industry relations. UCLAs premier scientists represent the new scientists of the 21st century. They act not only as scientists to create new knowledge, they also work as entrepreneurs to assure that breakthrough technology moves toward product development.

According to Belldegrun, the acquisition of Agensys by Astellas Pharma is a promising example of what can be done when entrepreneurial efforts by UCLA medical faculty are encouraged to blossom.

Venture capital investments in Agensys have come from premier groups such as Orbimed Associates, Alta Partners, Bear Sterns Health Innoventures, JAFCO, H&Q Healthcare, Duquesne Capital Management Co. and HBM Bioventures.


'/>"/>

Contact: Rachel Champeau
rchampeau@mednet.ucla.edu
310-794-0777
University of California - Los Angeles
Source:Eurekalert

Related biology news :

1. How the public perceives biotech
2. Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center
3. UK scientists working to help cut ID theft
4. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
5. Comet probes reveal evidence of origin of life, scientists claim
6. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
7. Male elephants get photo IDs from scientists
8. Scientists retrace evolution with first atomic structure of an ancient protein
9. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
10. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
11. Clemson scientists shed light on molecules in living cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/15/2016)... 2016 --> --> ... Market Research "Digital Door Lock Systems Market - Global Industry ... the global digital door lock systems market in terms of ... is forecast to grow at a CAGR of 31.8% during ... medium enterprises (MSMEs) across the world and high industrial activity ...
(Date:3/11/2016)... March 11, 2016 http://www.apimages.com ) - ... Picture is available at AP Images ( http://www.apimages.com ) - ... be used to produce the new refugee identity cards. DERMALOG will ... at CeBIT in Hanover next week.   ... will be used to produce the new refugee identity cards. DERMALOG ...
(Date:3/9/2016)... YORK , March 9, 2016 This ... and future states of the RNA Sequencing (RNA Seq) ... segments such as instruments, tools and reagents, data analysis, ... Analyze various segments of the RNA-Sequencing market such as ... services Identify the main factors affecting each segment and ...
Breaking Biology News(10 mins):
(Date:5/3/2016)... New York, NY (PRWEB) , ... May 03, ... ... and NeuroTech NYC , the sensor and data driven conferences, will take ... include:, UnitedHealth's Vidya Raman-Tangella on incorporating technology -- ...
(Date:5/3/2016)... Calif (PRWEB) , ... May 03, 2016 , ... ... industry leading fertility clinics and IVF laboratories. A contingency of reproductive endocrinologists, including ... treat men and women experiencing infertility and to help them build families. , ...
(Date:5/2/2016)... ... May 02, 2016 , ... F.E.E.D. Co., the ... of their revolutionary, veterinarian-designed product for indoor cats. The NoBowl Feeding System replaces ... their food the way nature intended. NoBowls make cats happy and healthy. , ...
(Date:4/29/2016)... , April 29, 2016 ... Transparency Market Research "Separation Systems for Commercial Biotechnology ... Trends, and Forecast 2015 - 2023", the separation ... US$ 10,665.5 Mn in 2014 and is projected ... 2015 to 2023 to reach US$ 19,227.8 Mn ...
Breaking Biology Technology: